Prot #MO39196: A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locall

Project: Research project

Project Details

StatusFinished
Effective start/end date11/15/17 → 11/30/21

Funding

  • PRA Health Sciences (Prot #MO39196 // Prot #MO39196)
  • Genentech, Inc (Prot #MO39196 // Prot #MO39196)